Rani Therapeutics receives Nasdaq deficiency notice for MVLS below $50M

Rani Therapeutics Holdings, Inc.

Nasdaq notified Rani on May 1, 2025 that its Market Value of Listed Securities was below $50M for 30 consecutive business days.
Company has 180 calendar days, until October 28, 2025, to regain compliance by achieving MVLS >= $50M for 10 consecutive business days.
If noncompliance persists, Nasdaq may delist; Rani could appeal or apply to transfer to Nasdaq Capital Market.
Rani is considering actions to regain compliance but has not yet decided on a response.
There is no assurance of regaining compliance or meeting other listing criteria.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.